Alterations in the basal ganglia in patients with brain tumours may be due to excessive iron deposition

Oncology Letters

Volumn 9, Issue 1, 2015, Pages 43-46

  Herynek, Vít ^a   Wagnerová, Dita ^a   Malucelli, Alberto ^b   Vymazal, Josef ^c   Sameš, Martin ^b   Hájek, Milan ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b J E PURKINJE UNIVERSITY   (Czech Republic)

^c NA HOMOLCE HOSPITAL   (Czech Republic)

Author keywords

Basal ganglia; Brain tumours; Iron; Magnetic resonance imaging; Oxidative stress

Indexed keywords

FERRITIN; IRON;

ADULT; ARTICLE; BASAL GANGLION; BRAIN TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IRON DEPOSITION; IRON METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; RELAXATION TIME; RELAXOMETRY; SUSCEPTIBILITY WEIGHTED IMAGING; THALAMUS; TUMOR RECURRENCE; WHITE MATTER;

EID: 84911419035     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2638     Document Type: Article

References (20)

1. Hallgren B and Sourander P: The effect of age on the non-haemin iron in the human brain. J Neurochem 3: 41-51, 1958.
2. Vymazal J, Babis M, Brooks RA, Filip K, Dezortova M, Hrncarkova H and Hajek M: T1 and T2 alterations in the brains of patients with hepatic cirrhosis. AJNR Am J Neuroradiol 17: 333-336, 1996.
3. Wolozin B and Golts N: Iron and Parkinson's disease. Neuroscientist 8: 22-32, 2002.
4. Correia S, Hubbard E, Hassenstab J, et al: Basal ganglia MR relaxometry in obsessive-compulsive disorder: T2 depends upon age of symptom onset. Brain Imaging Behav 4: 35-45, 2010.
5. Hájek M, Adamovičová M, Herynek V, Škoch A, Jírů F, Krepelová A and Dezortová M: MR relaxometry and 1H MR spectroscopy for the determination of iron and metabolite concentrations in PKAN patients. Eur Radiol 15: 1060-1068, 2005.
6. Toyokuni S: Iron-induced carcinogenesis: The role of redox regulation. Free Radic Biol Med 20: 553-566, 1996.
7. Evans AE, D'Angio GJ, Propert K, Anderson J and Hann HW: Prognostic factor in neuroblastoma. Cancer 59: 1853-1859, 1987.
8. Potaznik D, Groshen S, Miller D, Bagin R, Bhalla R, Schwartz M and de Sousa M: Association of serum iron, serum transferrin saturation and serum ferritin with survival in acute lymphocytic-leukemia. Am J Pediat Hematol Oncol 9: 350-355, 1987.
9. Richmond HG: Induction of sarcoma in the rat by iron-dextran complex. Br Med J 1: 947-949, 1959.
10. Huang X: Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res 533: 153-171, 2003.
11. Sato Y, Honda Y, Asoh T, Oizumi K, Ohshima Y and Honda E: Cerebrospinal fluid ferritin in glioblastoma: evidence for tumor synthesis. J Neurooncol 40: 47-50, 1998.
12. Richardson DR, Kalinowski DS, Lau S, Jansson PJ and Lovejoy DB: Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta 1790: 702-717, 2009.
13. Vymazal J, Urgosík D and Bulte JW: Differentiation between hemosiderin-and ferritin-bound brain iron using nuclear magnetic resonance and magnetic resonance imaging. Cell Mol Biol (Noisy-le-grand) 46: 835-842, 2000.
14. Schenker C, Meier D, Wichmann W, Boesiger P and Valavanis A: Age distribution and iron dependency of the T2 relaxation time in the globus pallidus and putamen. Neuroradiology 35: 119-124, 1993.
15. Herynek V, Wagnerová D, Hejlová I, Dezortová M and Hájek M: Changes in the brain during long-term follow-up after liver transplantation. J Magn Reson Imaging 35: 1332-1337, 2012.
16. Dusek P, Jankovic J and Le W: Iron dysregulation in movement disorders. Neurobiol Dis 46: 1-18, 2012.
17. Steegmann-Olmedillas JL: The role of iron in tumour cell proliferation. Clin Transl Oncol 13: 71-76, 2011.
18. Deugnier Y: Iron and liver cancer. Alcohol 30: 145-150, 2003.
19. Jian J, Yang Q, Dai J, Eckard J, Axelrod D, Smith J and Huang X: Effects of iron deficiency and iron overload on angiogenesis and oxidative stress - a potential dual role for iron in breast cancer. Free Radic Biol Med 50: 841-847, 2011.
20. Richardson DR: Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol 42: 267-281, 2002.